Company Profile

Bionex Pharmaceuticals LLC
Profile last edited on: 1/9/17      CAGE: 4VE50      UEI: GXNYB1PG22A3

Business Identifier: Drug development based on novel delivery systems
Year Founded
2007
First Award
2008
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

675 Us Highway One
North Brunswick, NJ 08902
   (732) 309-2419
   hocktan@bionexpharma.com
   www.bionexpharma.com
Location: Single
Congr. District: 12
County: Middlesx

Public Profile

Bionex Pharmaceuticals LLC is an emerging private specialty pharmaceutical development company founded in June 2007 with a mission to develop novel drug delivery technologies and specialty pharmaceutical products. Bionex is developing innovative pharmaceutical and consumer products employing novel delivery systems to improve onset time, drug bioavailability, and improved efficacy as well as address unmet medical needs. These products seek to improve the quality of life of patients that are suffering from an array of diseases and conditions.Bionex has developed several novel proprietary drug delivery (thin-film, coating, and device) technologies with many applications for pharmaceuticals and skin-care products. Bionex’s Core Technologies include: Transmucosal Drug Delivery, Transdermal Delivery, Intra-vaginal Delivery, Topical/Local Delivery. Bionex capabilities are its expertise in pharmaceutical formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in GMP facility, and well-connected network of industrial and academic consultants/advisors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $225,000
Project Title: Abuse Deterrent Transdermal Drug Delivery System for Fentanyl
2013 2 NIH $895,358
Project Title: Oral Transmucosal Drug Delivery System For Naltrexone For Alcohol Dependence Trea
2008 1 NIH $117,968
Project Title: Oral Transmucosal Drug Delivery System For Nicotine

Key People / Management

  Hock Tan -- President

  Siew L Chung

Company News

There are no news available.